Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 11.0 MILLION COMMON SHARES.CATALYST-PLANS …
Catalyst Pharmaceuticals CPRX stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic …
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Catalyst Pharmaceuticals, Inc. …
Shares in Catalyst Pharmaceuticals (NASDAQ:CPRX) crashed more than 40% after the firm, which is developing therapies for people with rare debilitating diseases, received a 'Refusal to File' letter from the US FDA. Shares lost 40.59% on …
Nexvet Biopharma Plc (NVET): NVET stock is down 2.01% today. Catalyst Pharmaceutical Partners (CPRX): CPRX stock is up 2.72% today. Fortress Biotech Inc (FBIO): FBIO stock is up 1.75% today. Cidara Therapeutics Inc (CDTX): CDTX …
Catalyst Pharmaceuticals, Inc. CPRX is expected to report first-quarter 2017 results on May 11. Last quarter, the company recorded a positive earnings surprise of 16.67%. Also, it topped expectations in all of the last four quarters with average …
Catalyst Pharmaceuticals, Inc. CPRX reported a loss of 6 cents per share in the first ... with an average beat of 372.02%. The stock has rallied 68.9% so far this year. Catabasis’ loss estimates narrowed from $1.09 to 90 cents for 2018 and …